الفهرس 
Aim of the workOnly 14 pages are availabe for public view
 |  | from | 258 |  |  |
| | | from | 258 | | |
Abstract
This study aimed to estimate the pre and posttreatment serum levels of glycosaminglycans (GAGs), soluble p55 tumor necrosis factor receptor (sp55TNFR) and soluble Lselectin in order to evaluate their prognostic significance and their role in monitoring tumor growth and hosttumor response in malignant lymphomas. Also, the work aimed to investigate the relationship between these levels with B symptoms and disease stage. For this purpose, 43 newly diagnosed patients with malignant lymphoma (12 with Hodgkin?s disease (HD) and 31 with NonHodgkin?s lymphoma (NHL). Among NHL patients, 7 were in stage I/II, 13 in stage III and 14 in stage IV. In addition, 10 NHL patients were presented with B symptoms while, 21 did not (B symptoms are defined as, unexplained fever with temperature above 38oC, unexplained weight loss of 10% of body weight over 6 months and night sweats. 7 apparently healthy individuals were selected as a control reference group. Results: 1Pretreatment levels of GAGs, sp55TNFR and sLselectin increased significantly in both HD and NHL before treatment as compared to control. Pretreatment sp55TNFR levels in both diseases and sLselectin (only in HD patients) may have a significant value in predicting response to therapy, while GAGs level in both diseases and sLselectin in NHL patients had a limited value in such prediction. 2 In contrast to sp55TNFR and sLselectin, posttreatment GAG levels are thought to be a good sign of remission in both HD and NHL. 3 Serum GAG levels increased significantly before treatment in stages III/IV NHL as compared to stage I/II, so serum GAGs at diagnosis could reflect tumor bulk and the disease activity. 4 Elevated serum sp55TNFR before treatment was associated with the presence of B symptoms and such association lead to a worse prognosis.